158 related articles for article (PubMed ID: 26183605)
1. In vivo pharmacokinetic and tissue distribution investigation of sustained-release cisplatin implants in the normal esophageal submucosa of 12 beagle dogs.
Yin JX; Wei Z; Xu JJ; Sun ZQ
Cancer Chemother Pharmacol; 2015 Sep; 76(3):525-36. PubMed ID: 26183605
[TBL] [Abstract][Full Text] [Related]
2. Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe intracorporeal nebulization catheter.
Selting K; Waldrep JC; Reinero C; Branson K; Gustafson D; Kim DY; Henry C; Owen N; Madsen R; Dhand R
J Aerosol Med Pulm Drug Deliv; 2008 Sep; 21(3):255-68. PubMed ID: 18759657
[TBL] [Abstract][Full Text] [Related]
3. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin pharmacokinetics and its nephrotoxicity in diabetic rabbits.
Najjar TA; Saad SY
Chemotherapy; 2001; 47(2):128-35. PubMed ID: 11173815
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3- dioxolane]platinum(II), as determined by ex vivo pharmacodynamics.
Kim DK; Kim HT; Tai JH; Cho YB; Kim TS; Kim KH; Park JG; Hong WS
Cancer Chemother Pharmacol; 1995; 37(1-2):1-6. PubMed ID: 7497577
[TBL] [Abstract][Full Text] [Related]
6. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice.
Júnior AD; Mota LG; Nunan EA; Wainstein AJ; Wainstein AP; Leal AS; Cardoso VN; De Oliveira MC
Life Sci; 2007 Jan; 80(7):659-64. PubMed ID: 17141809
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat.
Vadiei K; Siddik ZH; Khokhar AR; al-Baker S; Sampedro F; Perez-Soler R
Cancer Chemother Pharmacol; 1992; 30(5):365-9. PubMed ID: 1505075
[TBL] [Abstract][Full Text] [Related]
8. Nonuniform alteration of cis-diamminedichloroplatinum(II) tissue distribution in dogs with whole body hyperthermia.
Riviere JE; Page RL; Rogers RA; Chang SK; Dewhirst MW; Thrall DE
Cancer Res; 1990 Apr; 50(7):2075-80. PubMed ID: 2317796
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic behaviour of cisplatin in peritoneal fluid after intraperitoneal administration of cisplatin-loaded microspheres.
Tamura T; Imai J; Matsukawa Y; Horikiri Y; Suzuki T; Yoshino H; Ike O
J Pharm Pharmacol; 2001 Oct; 53(10):1331-9. PubMed ID: 11697540
[TBL] [Abstract][Full Text] [Related]
10. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
Nagai N; Ogata H
Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
[TBL] [Abstract][Full Text] [Related]
11. Experimental study on paratumoral injection of cisplatin-loaded microspheres for gastric cancer.
Narita K; Ikuta H; Hamabe Y; Kuroda Y
Kobe J Med Sci; 1999 Oct; 45(5):229-43. PubMed ID: 10853189
[TBL] [Abstract][Full Text] [Related]
12. Antigenotoxic properties of chlorophyll b against cisplatin-induced DNA damage and its relationship with distribution of platinum and magnesium in vivo.
Serpeloni JM; Batista BL; Angeli JP; Barcelos GR; Bianchi Mde L; Barbosa F; Antunes LM
J Toxicol Environ Health A; 2013; 76(6):345-53. PubMed ID: 23557233
[TBL] [Abstract][Full Text] [Related]
13. In vitro characteristics and in vivo plasma disposition of cisplatin conjugated with oxidized and dicarboxymethylated dextrans.
Nakashima M; Ichinose K; Kanematsu T; Masunaga T; Ohya Y; Ouchi T; Tomiyama N; Sasaki H; Ichikawa M
Biol Pharm Bull; 1999 Jul; 22(7):756-61. PubMed ID: 10443480
[TBL] [Abstract][Full Text] [Related]
14. Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer.
Sugiyama T; Kumagai S; Nishida T; Ushijima K; Matsuo T; Yakushiji M; Hyon SH; Ikada Y
Anticancer Res; 1998; 18(4B):2837-42. PubMed ID: 9713471
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and tissue distribution of iv injection of polyphase liposome-encapsulated cisplatin (KM-1) in rats.
Wang S; Mi JB; Li YZ; Chang WB; Ci YX; Zhao MZ; Zhao YK; Zhu LY; Xu G
Acta Pharmacol Sin; 2003 Jun; 24(6):589-92. PubMed ID: 12791187
[TBL] [Abstract][Full Text] [Related]
16. Heat-activated thermosensitive liposomal cisplatin (HTLC) results in effective growth delay of cervical carcinoma in mice.
Dou YN; Zheng J; Foltz WD; Weersink R; Chaudary N; Jaffray DA; Allen C
J Control Release; 2014 Mar; 178():69-78. PubMed ID: 24440663
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts.
Johnsson A; Olsson C; Nygren O; Nilsson M; Seiving B; Cavallin-Stahl E
Cancer Chemother Pharmacol; 1995; 37(1-2):23-31. PubMed ID: 7497593
[TBL] [Abstract][Full Text] [Related]
19. Reduction of systemic exposure and toxicity of cisplatin by encapsulation in poly-lactide-co-glycolide.
Verrijk R; Smolders IJ; Bosnie N; Begg AC
Cancer Res; 1992 Dec; 52(23):6653-6. PubMed ID: 1423309
[TBL] [Abstract][Full Text] [Related]
20. [Lethal effects of nanoliposome encapsulated cisplatin on Saos-2 cells and its distribution in nude mice bearing human].
Wang GW; Guo W; Tang XD; Peng CL; Zhao H
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):525-30. PubMed ID: 19829667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
